Sami Corwin, an analyst from William Blair, has initiated a new Buy rating on Crispr Therapeutics AG (CRSP).
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sami Corwin has given his Buy rating due to a combination of factors highlighting Crispr Therapeutics AG’s strategic advancements and promising product pipeline. The company’s collaboration with Vertex Pharmaceuticals on Casgevy for sickle cell disease and transfusion-dependent β-thalassemia is a pivotal point, with more than 50 authorized treatment centers activated worldwide and over 50 patients initiating cell collection. This indicates a robust rollout and potential revenue growth, with significant patient treatment expected to ramp up.
Additionally, Crispr Therapeutics’ strategic partnership with Nkure Therapeutics to co-develop CTX112, targeting CD19-positive B-cell malignancies, and the ongoing Phase I trials for in vivo gene-editing assets CTX310 and CTX320, signal strong future opportunities. With anticipated updates in the first half of 2025, these developments underscore the firm’s potential for significant growth, making it a compelling investment opportunity.
According to TipRanks, Corwin is a 4-star analyst with an average return of 6.7% and a 38.10% success rate. Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, CARGO Therapeutics, Inc., and Sarepta Therapeutics.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $86.00 price target.